Vaxcyte, Inc. (PCVX) is a publicly traded company in the Unknown sector. Across all available filings, 25 corporate insiders have executed 641 transactions totaling $124.1M, demonstrating a bearish sentiment with -$82.7M in net insider flow. The most recent transaction on Jan 15, 2026 involved a transaction of 6,750 shares valued at $0.
No significant insider buying has been recorded for PCVX in the recent period.
No significant insider selling has been recorded for PCVX in the recent period.
Based on recent SEC filings, insider sentiment for PCVX is bearish with an Insider Alignment Score of 17/100 and a net flow of -$82.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Vaxcyte, Inc. (PCVX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 25 insiders are actively trading PCVX stock, having executed 641 transactions in the past 90 days. The most active insider is Grant Pickering (Executive), who has made 189 transactions totaling $30.0M.
Get notified when executives and directors at PCVX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | Brandicourt Olivier | Executive | Award | 6,750 | $N/A | $0 | |
| Jan 15, 2026 | Brandicourt Olivier | Executive | Award | 1,357 | $N/A | $0 | |
| Jan 14, 2026 | Pickering Grant | Executive | Gift | 100,000 | $N/A | $0 | |
| Dec 23, 2025 | Cowan Elvia | Executive | Gift | 1,000 | $N/A | $0 | |
| Dec 23, 2025 | Cowan Elvia | Executive | Sale | 4,907 | $47.90 | $235.0K | |
| Dec 23, 2025 | Cowan Elvia | Executive | Sale | 6,716 | $47.94 | $322.0K | |
| Sep 8, 2025 | Pickering Grant | Executive | Payment | 7,356 | $32.41 | $238.4K | |
| Sep 8, 2025 | Guggenhime Andrew | Executive | Payment | 2,890 | $32.41 | $93.7K | |
| Sep 8, 2025 | Wassil Jim | Executive | Payment | 2,759 | $32.41 | $89.4K | |
| Sep 8, 2025 | S. Dhaliwal Harpreet | Executive | Payment | 1,204 | $32.41 | $39.0K | |
| Sep 8, 2025 | Cowan Elvia | Executive | Payment | 482 | $32.41 | $15.6K | |
| Sep 7, 2025 | Cowan Elvia | Executive | Award | 2,810 | $N/A | $0 | |
| Sep 2, 2025 | Pickering Grant | Executive | Payment | 2,857 | $31.56 | $90.2K | |
| Sep 2, 2025 | Pickering Grant | Executive | Payment | 3,420 | $31.56 | $107.9K | |
| Sep 2, 2025 | Pickering Grant | Executive | Payment | 4,563 | $31.56 | $144.0K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 394 | $103.4M | 75.7% |
Purchase(P) | 4 | $20.7M | 15.1% |
Payment(F) | 47 | $7.3M | 5.3% |
Exercise(M) | 137 | $5.3M | 3.8% |
Award(A) | 44 | $28.7K | 0.0% |
Gift(G) | 3 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Conversion(C) | 11 | $0 | 0.0% |
Insider selling pressure at Vaxcyte, Inc. has increased, with 25 insiders executing 641 transactions across all time. Total sales of $103.4M significantly outpace purchases of $20.7M, resulting in a net outflow of $82.7M. However, 48% of these transactions are pre-scheduled 10b5-1 plans, often used for tax planning or diversification rather than signaling negative outlook.